Why clinical trial delays matter
A delay in a clinical trial can mean a drop in a drug's net value, lost ground to competitors, or an increased risk of failure — or it can signal more bad news to come. But not all trial delays are red flags. How often is it a minor inconvenience? And how can you predict the difference? It's not as easy as it sounds: It can be hard to get full information about trial delays, and details are often even sparser if the sponsor is a large pharma company or a private biotech.
In this special STAT Report, the first of three on clinical trials, biopharma consultant Frank David, M.D., Ph.D., provides the answers that people who track the progress of clinical trials need most.
Exclusive Offer
Purchase the report now for $149 and access valuable insights on clinical trial delays and how to predict the difference between minor inconveniences and major red flags. You will also receive one month of access to STAT Trials Pulse, AppliedXL's AI-powered platform that automates clinical trials intelligence, saving you time and surfacing early risk indicators.
GET THE REPORT
About STAT Reports
STAT Reports help business executives, researchers, consultants, and analysts navigate the ever-changing life sciences industry. Each report provides deep analysis of a particular issue in health care. Pick and purchase the reports that are most relevant to you.
LEARN MORE
Other topics include:
No comments